Aktuellt
SENASTE
Episurf Medical last night reported preliminary Q3 results as well as a capital raise of cSEK159m, which should secure its financial position into 2025, well past all important value inflection points regarding the EPIC Knee trial and potential 510(k) approval for the patellofemoral and MTP1-joint (big toe) implants in the US. We have updated our forecasts, and in turn lifted our fair value to SEK3.5–9.5 (previously SEK2.7–8.2).
LÄS MER
